Xeno Laboratories Trestolone 50 mg/ml MENT Research Vial

MENT is the abbreviation of 7-alpha-methyl-19-nortestosterone, and Trestolone is its common name. It is a 19-nor androgen with a methyl group at position seven, which raises its potency per milligram well above testosterone. It acts on the androgen receptor, behaves as a progestogen, and strongly suppresses luteinising hormone and follicle stimulating hormone. It was studied by the Population Council for male contraception and androgen replacement but was never marketed.

Yes, but not into the usual estrogen. The compound is converted by aromatase into 7-alpha-methylestradiol, and that molecule is not reliably measured by standard estradiol immunoassays, so a normal looking estradiol result does not prove that the pathway is quiet. Reference material therefore treats estrogen handling as something to follow deliberately, and water retention is described as moderate rather than absent for this compound.

The form carried in this line is the short ester, and vendor profiles put its half-life at about a day with activity of roughly two days, which is why daily or every-other-day injection appears in reference protocols. No independent pharmacokinetic study confirming either figure was found, and the ester itself is not printed on the storefront row, so the exact release profile of this specific vial remains unconfirmed.

Suppression of the axis is the most consistent finding, and it is described as close to complete, so natural testosterone production stops while the compound is present. Progestogenic activity is part of the profile, as is moderate water retention through the aromatisation pathway. The reference literature does not describe the liver injury pattern seen with 17-alpha-alkylated orals, because trestolone is not alkylated in that way. No human safety study of this vial exists.

There are no published clinical doses for this compound, so the only figures available are community practice: roughly 10 mg per day at the entry point, 25 to 50 mg per day at the upper end, over blocks of six to ten weeks, with injections daily or every other day. The upper edge of that range is where reports of suppression and estrogen-linked effects become more common. These are practice figures quoted for context, not a recommendation.

This vial is listed as research material with international checkout and a U.S. domestic option. Orders are handled within one to two business days and each batch ships with an HPLC report and a Certificate of Analysis. Stock, variant and the current price are shown in the product block above; at the time of checking, the listing carried an out of stock marker while packs are restocked, so confirm the stock line before ordering.